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Objective: The aim of the present study was to investigate the effects of diabetes mellitus (DM) on
ovarian reserve and injury by considering laboratory and histopathological parameters in rat models.
Materials and methods: An experimental DM model was created in 16 rats. Eight rats with normal blood
glucose levels were included in the control group. Diabetic rats were divided randomly into two groups:
nontreated and resveratrol-treated groups. Histopathological examination and nuclear factor (NF)-kB
immunoexpression level determination were performed. Plasma malondialdehyde, glutathione,
pentraxin-3, and anti-Müllerian hormone levels were measured. Relations between the variables were
compared by Student t test, analysis of variance, and ManneWhitney U and c2 tests.
Results: We found statistically signiﬁcantly lower glutathione and anti-Müllerian hormone levels, and
higher malondialdehyde and pentraxin-3 levels in nontreated diabetic group when compared with the
control and resveratrol-treated diabetic groups. Stromal degeneration, follicle degeneration, stromal
ﬁbrosis scores, and NF-kB immunoexpression levels were signiﬁcantly higher in nontreated diabetic rats.
Primordial and primary follicle counts were signiﬁcantly lower in the nontreated diabetic group when
compared with the control and resveratrol-treated groups. There was no statistically signiﬁcant differ-
ence in secondary and tertiary follicles between these groups.
Conclusion: These ﬁndings provide strong evidence that the ovarian follicle pool in nontreated diabetic
rats is affected in the early stages of the follicle development process. We precluded negative effects of
DM on ovaries by inhibiting the NF-kB pathway with resveratrol. We thought that the NF-kB pathway
plays a role in the pathophysiology of ovarian failure in diabetic rats. Further studies should evaluate this
precise mechanism that leads to a decline in the anti-Müllerian hormone levels. In addition, the rela-
tionship between this abnormality and reproductive function in diabetic patients should be analyzed
further.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Hyperglycemia causes tissue damage through ﬁve mechanisms:
polyol pathway, protein kinase-C isoform activation, hexosamine
pathway, increased intracellular formation of advanced glycation
end products (AGEs), and increased expression of AGE receptoryePerinatology Department,
koy, Manisa 45210, Turkey.
).
bstetrics & Gynecology. Published(RAGE) and its ligands. Literature data indicate that all these
mechanisms are activated by overproduction of mitochondrial
reactive oxygen species (ROS) [1]. Oxidative stress is considered to
be one of the pathogenic mechanisms for diabetes and its
complications.
AGEs are formed by nonenzymatic reaction of glucose and other
glycating components derived from glucose and fatty acid oxida-
tion in endothelial cells [2,3]. AGEs increase in the extracellular
matrix in diabetes mellitus (DM) [4,5]. RAGE induces the produc-
tion of ROS, which activates the pleiotropic transcription factor
nuclear factor (NF)-kB. Activation of the NF-kB pathway induces theby Elsevier Taiwan LLC. All rights reserved.
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cytokines such as tumor necrosis factor (TNF) and interleukin-1 [6].
Vascular endothelial cell damage is aggravated by increased levels
of AGEs and ROS. Endothelial dysfunction leads to vascular com-
plications of DM [7].
Literature data conﬁrmed that resveratrol has shown antioxi-
dant, antiplatelet, anticancer, anti-inﬂammatory, and life-span
extending effects in various experimental models [8,9]. Jing et al
[10] showed that resveratrol alleviates DM-induced vasculopathy
through attenuation of RAGE for the AGE NF-kB signaling pathway.
Pentraxin-3 (PTX3) is a member of the long pentraxin family
and has a C-terminal sequence showing homology with short
pentraxins such as C-reactive protein. PTX3 is produced in different
cell components of atherosclerotic lesions, including endothelial
cells, macrophages, ﬁbroblasts, vascular smooth muscle cells, and
adipocytes. That is to say, the plasma level of PTX3 reﬂects local
inﬂammation at the atherosclerotic lesion site [11]. As PTX3 syn-
thesis occurs at sites of inﬂammation, it is believed to be a correct
independent indicator of disease activity [12].
Womenwith DM have a delayed age at menarche. They also face
menstrual irregularities with a higher prevalence than nondiabetic
women of similar age [13]. One-third of women with DM have
problems such as amenorrhea, polymenorrhea, and oligomenor-
rhea throughout their reproductive years. This is approximately
double the prevalence of menstrual disorders observed among
women without the disease [13]. Moreover, women with DM
experience menopause signiﬁcantly earlier than women without
the disease [14].
Several reports have suggested an autoimmune etiology for
premature menopause in DM. Approximately 20e40% of women
with premature ovarian failure also have autoimmune disorders
[15,16]. Contrary to these data, in our previous study [17], we
showed that glucose toxicity in diabetic rat ovaries occurs by the
NF-kB pathway.
Several studies investigated menstrual disorders and ovarian
reserve in diabetic patients [13,18]. Ovarian reserve and function in
diabetic women play important roles in fertility, cardiovascular
disease risk, and osteoporosis. In the present study, we aimed to
investigate the effects of DM on ovarian reserve and injury in terms
of laboratory and histopathological ﬁndings in a rat model.
Materials and methods
Animals
Twenty-four female Sprague-Dawley albino mature rats
(Gaziosmanpasa University, Tokat, Turkey) at 8 weeks, weighing
200e220 g, were included in this study. Animals were fed ad libi-
tum and housed in pairs in steel cages having a temperature-
controlled environment (22 ± 2C) with 12-hour light/dark cy-
cles. The experimental procedures were approved by the Com-
mittee for Animal Research of Gaziosmanpasa University, Tokat,
Turkey. All animal studies strictly conform to the animal experi-
ment guidelines of the Committee for Human Care.
Experimental protocol
Diabetes was induced by intraperitoneal (i.p.) injection of STZ
(Sigma-Aldrich, Inc., Saint Louis, MO, USA; 60 mg/kg in 0.9% NaCl,
adjusted to a pH of 4.0 with 0.2 M sodium citrate) in 16 rats. Dia-
betes was veriﬁed by evaluating blood glucose levels with glucose
oxidase reagent strips (Boehringer-Mannheim, Indianapolis, IN,
USA) after 24 hours. Rats with 250 mg/dL and higher blood glucose
levels were accepted as diabetic and included in this study. Eight
rats with normal blood glucose levels (<120 mg/dL) were taken asthe control group. Placebo (i.p. 0.9% NaCl) was given to the control
group. We waited 7 weeks for diabetic complications to develop in
diabetic rats. Then 16 diabetic rats were randomly divided into two
groups; Group 1, treated with 1 mL/kg 0.9% NaCl i.p. (n ¼ 8; non-
treated diabetic group) and Group 2, treated with 20 mg/kg/day
resveratrol i.p. (Sigma-Aldrich, Inc.; n¼ 8) for 4 weeks (resveratrol-
treated diabetic group).
After these procedures, the animals were euthanized, and blood
samples were collected by cardiac puncture for biochemical anal-
ysis. Bilateral oophorectomy was performed for histopathological
examination.
Histopathological examination
For histological and immunohistochemical studies, all animals
were anesthetized with i.p. ketamine (40 mg/kg)/xylazine (4 mg/
kg) injection and perfusedwith 200mL of 4% formaldehyde in 0.1M
phosphate-buffer saline. Formalin-ﬁxed ovary sections (4 mm)were
stained with hematoxylin and eosine. All sections were photo-
graphed using an Olympus C-5050 digital camera; Olympus Optical
Co., Tokyo, Japan mounted on an Olympus BX51 microscope;
Olympus Optical Co., Tokyo, Japan.
Follicular degeneration, stromal degeneration, and stromal
ﬁbrosis were scored from 0 to 3 according to the degree of injury,
where 0 indicates no pathological ﬁnding, and 1, 2, and 3 indicate
pathological ﬁndings observed in <33%, 33e66%, and >66% of the
ovarian section, respectively.
Follicles were counted according to the follicle morphology
described as follows: (1) Primordial follicle: Follicle is surrounded by
a thin, single layer of follicular epithelial cells; (2) Primary follicle:
the follicular epithelium surrounding the oocyte becomes iso-to
highly prismatic; (3) Secondary follicle: the follicular epithelium
encompassing multiple rows are engendereddthe so-called stra-
tum granulosum. Zona pellucida and thecal cells may also be seen;
and (4)Tertiary follicle: its identifying characteristics are ﬂuid-ﬁlled
cavity and antral follicle.
Morphological analysis was assessed by computerized image
analysis system (Image-Pro Express 1.4.5; Media Cybernetics, Inc.,
Rockville, MD, USA). Ten microscopic ﬁelds under 10 objective
were evaluated per section.
NF-kB immunoexpression
For immunohistochemical examination, sections were incu-
bated with H2O2 (10%) for 30 minutes to eliminate endogenous
peroxidase activity and blocked with 10% normal goat serum
(Invitrogen, Carlsbad, California, USA) for 1 hour at room temper-
ature. Subsequently, sections were incubated with primary anti-
bodies (NF-kB, Santa Cruz Biotechnology, Dallas, Texas, USA; 1/100)
for 24 hours at 4C. Antibody detection was performed with the
Histostain-Plus Bulk kit (Invitrogen, Carlsbad, California, USA)
against rabbit immunoglobulin G, and 3,30-diaminobenzidine was
used to visualize the ﬁnal product. Photos were taken by an
Olympus C-5050 digital camera mounted on an Olympus BX51
microscope. Brown cytoplasmic staining in ovarian stromal cells
and oocyte was scored as positive for NF-kB. The number of NF-kB
(þ) cells was determined by systematically scoring at least 100
ovarian stromal cells per ﬁeld in 10 ﬁelds of tissue sections at 10
objective.
Measurement of lipid peroxidation
Lipid peroxidation was evaluated in plasma samples by
measuring malondialdehyde (MDA) levels, as it is a thiobarbituric
acid reactive substance [19]. Brieﬂy, trichloroacetic acid and
Table 1
GSH, MDA, AMH, and PTX-3 levels in control and diabetic rats.
GSH (mM) MDA (mM) AMH (ng/mL) PTX-3 (ng/mL)
Control rats 12.26 ± 2.18 0.14 ± 0.09 2.45 ± 0.18 1.17 ± 0.16
Nontreated
diabetic rats
1.55 ± 0.53 0.37 ± 0.04 1.59 ± 0.23 2.58 ± 0.09
Resveratrol-treated
diabetic rats
10.19 ± 2.15 0.26 ± 0.05 2.14 ± 0.16 1.98 ± 0.33
Data are expressed as mean ± SEM.
AMH ¼ anti-Müllerian hormone; GSH ¼ glutathione; MDA ¼ malondialdehyde;
PTX-3 ¼ pentraxin-3; SEM ¼ standard error of the mean.
Table 2
Histological scores of ovaries in control and diabetic rats.
Control rats Nontreated
diabetic rats
Resveratrol-treated
diabetic rats
Stromal degeneration 0.10 ± 0.08 2.48 ± 0.25 1.12 ± 0.16
Follicle degeneration 0.18 ± 0.10 2.62 ± 0.18 0.93 ± 0.11
Stromal ﬁbrosis 0.35 ± 0.09 2.37 ± 0.53 0.56 ± 0.32
NF-kB Immunoexpression (%) 5.86 ± 2.21 43.54 ± 5.75 28.55 ± 6.24
Data are expressed as mean ± SEM.
NF-kB ¼ nuclear factor kB; SEM ¼ standard error of the mean.
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plasma samples, and then they were mixed and incubated at 100C
for 60 minutes. After cooling on ice, the samples were centrifuged
at 603.72 g for 20 minutes, and the absorbance of the supernatant
was read at 535 nm. MDA levels were calculated from the standard
calibration curve using tetraethoxypropane and expressed in units
of micromoles.
Measurement of plasma glutathione levels
Glutathione (GSH) content in plasma samples was measured
spectrophotometrically according to Ellman's method [20]. In this
method, thiols interact with 5,50-dithiobis-(2-nitrobenzoic acid)
and form a colored anion with the maximum peak at 412 nm. GSH
levels were calculated from the standard calibration curve and
expressed in units of micromoles.
Measurement of plasma anti-Müllerian hormone levels
Plasma anti-Müllerian hormone (AMH) levels were measured
using a commercially available enzyme-linked immunosorbent
assay (ELISA) kit (Biosciences, Aalst, Belgium). The plasma samples
were diluted 1:2, and AMH level was determined according to the
manufacturer's recommendations.
Evaluation of plasma PTX3 levels
PTX3 levels were measured in each 100 mL sample by the
standard ELISA apparatus at 450 nm using a PTX3 kit (Uscn Life
Science Inc., Wuhan, China). PTX3 levels were determined in
duplicate according to the manufacturer's instructions. The detec-
tion range for PTX3 assay was 0.078e5 ng/mL.
Statistical analysis
Data analyses were performed by SPSS version 15.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). The groups of parametric vari-
ables were compared by Student t test and analysis of variance. The
groups of nonparametric variables were compared by Man-
neWhitney U test. Categorical variables were compared by c2 test.
Results were given as mean ± standard error of mean. A p value of
<0.05 was accepted as statistically signiﬁcant and that of p < 0.001
was accepted as statistically highly signiﬁcant.
Results
In the control group, plasma glucose levels (94.8 ± 7.2 mg/dL)
were signiﬁcantly lower than that in the nontreated diabetic group
(452.7 ± 43.6 mg/dL; p < 0.0001). GSH levels were signiﬁcantly
lower in nontreated diabetic rats when compared with the control
group (p ¼ 0.01). MDA levels were signiﬁcantly higher in non-
treated diabetic rats when compared with control rats (p ¼ 0.04).
AMH levels in nontreated diabetic rats were signiﬁcantly lower
than that in the control group (p ¼ 0.03). PTX3 levels in the non-
treated diabetic group were signiﬁcantly higher than those in the
control group (p ¼ 0.04). GSH levels were signiﬁcantly higher in
resveratrol-treated diabetic rats than in the nontreated diabetic
group (p < 0.001). MDA levels were signiﬁcantly higher in non-
treated diabetic rats than in resveratrol-treated diabetic rats
(p ¼ 0.005). AMH levels in nontreated diabetic rats were signiﬁ-
cantly lower than in resveratrol-treated diabetic group (p ¼ 0.005).
PTX3 levels in the nontreated diabetic group were signiﬁcantly
higher than those in the resveratrol-treated diabetic group
(p ¼ 0.003). The levels of GSH, MDA, AMH, and PTX3 are summa-
rized in Table 1.Stromal degeneration, follicle degeneration, stromal ﬁbrosis
scores, and NF-kB immunoexpression were signiﬁcantly higher in
nontreated diabetic rats when compared with control rats
(p < 0.001, p < 0.001, p < 0.001, and p < 0.0001, respectively), and
signiﬁcantly lower in resveratrol-treated diabetic rats when
compared with nontreated diabetic rats (p ¼ 0.03, p ¼ 0.01,
p ¼ 0.005, and p < 0.001, respectively). Histopathological scores of
stromal degeneration, follicle degeneration, stromal ﬁbrosis, and
NF-kB immunoexpression levels are shown in Table 2. Hematoxylin
and eosine-stained sections and NF-kB immunohistochemistry
slides of ovaries of control, nontreated, and resveratrol-treated
diabetic rats are shown in Fig. 1.
Primordial and primary follicle counts were signiﬁcantly lower
in the nontreated diabetic group when compared with the control
group (p¼ 0.02 and p¼ 0.03, respectively). However, there were no
signiﬁcant differences in secondary and tertiary follicles between
these two groups. In addition, primordial and primary follicle
counts were signiﬁcantly higher in the resveratrol-treated diabetic
group than in the nontreated diabetic group (p ¼ 0.03 and p¼ 0.04,
respectively). However, there were no signiﬁcant differences in
secondary and tertiary follicles between these two diabetic groups.
The results and graphics of primordial, primary, secondary, and
tertiary follicle counts are given in Table 3.Discussion
In recent years, hyperglycemia and a number of hyperglycemia-
related factors, including AGEs, have been linked to the complica-
tions of diabetes [21,22]. AGEs are formed by a complicated,
nonenzymatic, and irreversible process, which leads to the reduc-
tion of sugar groups to proteins, lipids, and nucleic acids. RAGE, a
member of the immunoglobulin family of cell surface receptors,
interacts with different ligands, especially AGEs [23]. Activation of
RAGE engages critical signaling pathways linked to downstream
responses, such as the NF-kB pathway [24]. The role of the NF-kB
pathway in response to AGEs has been investigated in macrophage
cell lines [25]. TNF-a and other proinﬂammatory cytokines, and the
potent angiogenic factor vascular endothelial growth factor are
regulated by NF-kB. The NF-kB pathway leads to ﬁbrosis of tissue
after inﬂammation [6]. Vascular endothelial growth factor induces
a proliferative response of vascular endothelial cells via speciﬁc
Fig. 1. Hematoxylin and eosin sections from rat ovary (10 magniﬁcation). (A) Control group: ovarian sections showing primordial follicle (pr), primary follicle (prm), and sec-
ondary follicle (sf). (B) Expression of NF-kB in the control group. (C) Nontreated diabetic rats: ovarian sections showing secondary follicle (sf), ﬁbrotic ovarian stroma (**),
inﬂammation (i), and follicle degeneration (fd). (D) Marked activation of NF-kB in nontreated diabetic rats. (E) Resveratrol-treated diabetic rats: ovarian sections showing primary
follicle (prm), corpus luteum (CL), and decreased stromal ﬁbrosis (**). (F) Expression of NF-kB in resveratrol-treated diabetic rats (100 magniﬁcation). NF-kB ¼ nuclear factor-kB.
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we showed that severe glucose toxicity occurs in diabetic rat
ovaries. This injury depends on the activation of the NF-kB pathway
in diabetic rats [17]. In the present study, we note that NF-kB
immunoexpression is signiﬁcantly higher in nontreated diabetic
rats. We ﬁnd out that DM had several negative effects on ovariesTable 3
Results of primordial, primary, secondary, and tertiary follicle counts in control,
nontreated diabetic, and resveratrol-treated diabetic rats.
Follicle Control rats Nontreated
diabetic rats
Resveratrol-treated
diabetic rats
Primordial 17.32 ± 4.65 7.84 ± 0.86 12.25 ± 2.14
Primary 12.86 ± 3.24 6.24 ± 2.85 10.48 ± 1.16
Secondary 10.26 ± 2.50 8.32 ± 1.15 8.45 ± 2.53
Tertiary 5.32 ± 1.04 4.45 ± 0.52 5.18 ± 1.75
Data are expressed as mean ± standard error of the mean.such as stromal ﬁbrosis, and stromal and follicle degeneration in rat
models. Moreover, the present study showed that resveratrol
treatment seems to ameliorate the negative ovarian effects of
oxidative stress through the NF-kB pathway.
Primary proinﬂammatory signals (bacterial products,
interleukin-1, and TNF) that are produced by different cell types
(predominantly macrophages and vascular endothelial cells)
[27,28] leads to the production of PTX3da true and direct indicator
of inﬂammationdfromvascular endothelial cells andmacrophages.
In the present study, we found signiﬁcantly high PTX3 levels in the
nontreated diabetic group when compared with the control group.
In addition, PTX3 levels in the resveratrol-treated diabetic group
were signiﬁcantly lower than those in the diabetic group.
These results indicate that PTX3 may be a good predictive
marker for the detection of the complications of DM on ovary and
premature ovarian failure. To minimize the incidence and potential
negative effects of premature ovarian failure, an accurate and early
diagnosis is essential. Further large-scale and prospective studies
O. Erbas et al. / Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 498e503502should evaluate whether PTX3 is a reliable marker of DM-related
ovarian injury or not.
Literature data conﬁrmed that oxidative stress plays a signiﬁ-
cant role in the pathogenesis of DM and its complications. ROS,
which are generated by endogenous processes, may promote the
development of DM complications [7,29]. Elimination or inhibition
of ROS may attenuate oxidative stress-induced damage and
improve the complications of DM. Therefore, we can say that
oxidative stress plays the key role in the progression of vascular
complications of DM. Accumulated epidemiologic data conﬁrm that
diabetes is usually accompanied by an increased production of free
radicals or impaired antioxidant defenses, which lead to the
development and progression of tissue and vascular complications
of diabetes [30].
Superoxide dismutase is an antioxidant enzyme that degrades
polyunsaturated lipids and forms MDA. MDA and superoxide dis-
mutase are used as biomarkers of oxidative stress in vivo. In our
study, MDA levels in nontreated diabetic rats were signiﬁcantly
higher when compared with the control group. Furthermore, MDA
levels in the resveratrol-treated diabetic group were signiﬁcantly
lower than those in the nontreated diabetic group. At the same
time, histological ﬁndings showed that ovaries of the diabetic rats
were impaired. Apparently, in DM, oxidative stress can exert
devastating effects on the ovary.
GSH is a major intracellular antioxidant. GSH and other thiols
maintain the redox balance of cells and prevent them from oxida-
tive damage. GSH-peroxidase catalyzes the oxidation of GSH to
GSSG and reduces hydrogen peroxides (H2O2) to water. To maintain
the balance between GSH and GSSG, the oxidized form of GSH
(GSSG) is reduced to GSH. In our study, we showed that GSH levels
are lower in the nontreated diabetic group. Further assessment of
the GSH/GSSG ratio and H2O2 can provide more information on the
oxidant and antioxidant balance status in DM.
AMH, a glycoprotein produced by the granulosa cells of small
ovarian follicles, decreases during menopausal transition. Sowers
et al [31] observed that serum AMH levels began to decline 10 years
before the ﬁnal menstrual period, and AMH levels reached a level
below the detection limit 5 years prior to menopause. By contrast,
the levels of estradiol and follicle stimulating hormone remained
normal until a couple of years before the cessation of menses
[32,33]. Soto et al [34] showed that AMH levels decrease earlier in
diabetic patients. Our data also showed an earlier decline in the
ovarian follicle pool, such as primordial and primary follicles, in the
nontreated diabetic group. As AMH synthesis by granulosa cells
starts in the primary follicles, the decline in AMH levels may be
associated with the decrease of primary follicle count in the non-
treated diabetic group. After resveratrol treatment, primordial and
primary follicle counts and AMH levels increased signiﬁcantly.
AMH is a marker that shows both follicle quality and follicle
quantity. Our study showed apparent follicle degeneration in the
nontreated diabetic group. Follicle degeneration is an indicator of
granulosa cell injury. Granulosa cell injury is probably due to the
direct effects of oxidative stress/NF-kB pathway activation and also
indirect effects of the disturbed microenvironment in DM. These
are the other possible mechanisms that can decline AMH levels.
The serum values of AMH, which is secreted by small follicles,
reﬂect the ovarian follicle pool [35]. In nondiabetic women,
apoptosis is the primary mechanism that reduces the follicle
number of the ovarian follicular pool [36]. Apoptotic mechanism is
exaggerated in diabetic animal studies [37]. Females are bornwith a
pool of ovarian follicles, which accompany them throughout their
reproductive life until menopause. The resting follicles can be
injured by environmental factors [38]. Granulosa cells are altered
when exposed to hyperglycemia, which has been recently
demonstrated in diabetic rat/animal models [37]. In addition,elevated serum glucose levels activate several mechanisms in the
ovarian aging process [38]. These studies have shown the presence
of altered metabolic pathways and maturation period of the folli-
cles, and additionally increased apoptosis in diabetic animal
models. Glycation of proteins may have a role in deteriorated
ovarian function in women with DM. The presence of AGEs and
activation of RAGE are involved in physiological ovarian aging [38].
In this study, we found that DM affects ovarian follicles, espe-
cially primordial and primary ones. These ﬁndings suggest that the
activation of pathogenic mechanisms inﬂuences follicle maturation
in the early stages of the period in diabetic rats. This phenomenon
most likely occurs at the oocyteecumulus cell complex and leads to
injuries through several pathways.We speculate that a nonimmune
mechanism; NF-kB pathway plays a role in the pathophysiology of
this ovarian complication. In addition, this study showed that
inhibiting the NF-kB pathway by antagonists ameliorates the
negative effects of oxidative stress on ovaries. Further studies
should evaluate this precise mechanism that leads to a decline in
AMH levels. In addition, the relationship between this abnormality
and reproductive function in diabetic patients should be further
analyzed.Conﬂicts of interest
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